CHINA NATIONAL ACCORD MEDICINES CORPORATION LTD. China National Accord Medicines Corporation Ltd. Share Price
Equities
000028
CNE0000009N6
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 35.11 CNY | -2.42% |
|
-0.31% | +21.11% |
| Sales 2024 * | 80.71B 11.14B 892B | Sales 2025 * | 85.88B 11.85B 949B | Capitalization | 18B 2.48B 199B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.78B 245M 19.63B | Net income 2025 * | 1.89B 261M 20.91B | EV / Sales 2024 * | 0.25 x |
| Net Debt 2024 * | 2.48B 342M 27.42B | Net Debt 2025 * | 3.35B 463M 37.04B | EV / Sales 2025 * | 0.25 x |
| P/E ratio 2024 * |
11
x | P/E ratio 2025 * |
10.3
x | Employees | 39,449 |
| Yield 2024 * |
2.16% | Yield 2025 * |
2.35% | Free-Float | 42.7% |
More Fundamentals
* Assessed data
More news
| 1 day | -2.42% | ||
| 1 week | -0.31% | ||
| Current month | +14.29% | ||
| 1 month | +17.31% | ||
| 3 months | +16.84% | ||
| 6 months | +22.21% | ||
| Current year | +21.11% |
1 week
33.80
36.60
1 month
29.8536.60
Current year
26.0636.60
1 year
26.0652.55
3 years
20.3852.55
5 years
20.3852.55
10 years
20.3872.39
| Managers | Title | Age | Since |
|---|---|---|---|
Zhao Xiong Lin
CEO | Chief Executive Officer | 57 | 30/11/08 |
Guo Lin Gu
DFI | Director of Finance/CFO | 49 | 27/05/20 |
Min Lin
CHM | Chairman | 59 | 30/11/08 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Min Lin
CHM | Chairman | 59 | 30/11/08 |
Yi Jian Wu
BRD | Director/Board Member | 54 | 12/11/20 |
Yong Liu
BRD | Director/Board Member | 55 | 31/12/16 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 35.11 | -2.42% | 6,372,578 |
| 25/04/24 | 35.98 | +2.95% | 6,057,706 |
| 24/04/24 | 34.95 | +2.52% | 6,009,046 |
| 23/04/24 | 34.09 | -4.59% | 7,990,845 |
| 22/04/24 | 35.73 | +1.45% | 7,113,052 |
End-of-day quote Shenzhen S.E., April 25, 2024
More quotes
China National Accord Medicines Corporation Ltd. is a China-based company principally engaged in the pharmaceutical wholesaling, retailing and manufacturing businesses. The Company's main products include antibiotic preparations, power injections, antibiotic Active Pharmaceutical Ingredients (APIs), respiratory system drugs and cardiovascular and cerebrovascular system drugs, among others. The Company is also involved in the provision of logistics and storage services, leasing services and training services, among others. The Company distributes its products mainly in domestic market.
Sector
Pharmaceuticals
Calendar
29/04/2024
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
35.11
CNY
Average target price
38.77
CNY
Spread / Average Target
+10.43%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +21.11% | 2.48B | |
| +17.35% | 71.39B | |
| +2.39% | 25.1B | |
| +5.38% | 8.59B | |
| +6.69% | 8.19B | |
| -20.96% | 7.91B | |
| +0.49% | 4.54B | |
| +17.12% | 4.31B | |
| -3.38% | 3.93B | |
| -2.61% | 3.86B |
- Stock Market
- Equities
- 000028 Stock
